Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Clin Virol ; 165: 105519, 2023 08.
Article in English | MEDLINE | ID: mdl-37321150

ABSTRACT

BACKGROUND: Human Cytomegalovirus (HCMV) is still one of the major concerning infection in hematopoietic stem cell transplant (HSCT) recipients. Letermovir (LTV) has been recently introduced for HCMV prophylaxis in adult patients who received allogeneic HSCT. However, many aspects related to immune reconstitution need to be further explored. The aim of this study was to define the prognostic role of HCMV-specific T-cell frequency measured at the end of LTV prophylaxis in predicting the risk for clinically significant HCMV infection (i.e. infection requiring antiviral treatment) after the stop of the prophylaxis. METHODS: Sixty-six adult patients who underwent allogeneic HSCT were enrolled and HCMV DNAemia was prospectively monitored. Additionally, HCMV-specific T-cell response was evaluated using ELISpot assay against two different antigens (HCMV infected cell lysate and pp65 peptide pool). RESULTS: Ten patients (15.2%) developed at least one positive HCMV DNAemia episode during LTV prophylaxis, whereas 50/66 (75.8%) patients developed at least one positive HCMV DNA event after LTV prophylaxis. Of note, 25 of them (50%) experienced a clinically significant HCMV infection. The median HCMV-specific T-cell response measured against HCMV lysate but not against pp65 peptide pool was lower in patients who developed HCMV clinically significant infection after prophylaxis. A ROC analysis revealed that the level of 0.04 HCMV-specific T cells/µl should be used as cut-off for development of clinically significant HCMV reactivation after prophylaxis. CONCLUSION: Assessment of HCMV-specific immunity upon discontinuation of universal prophylaxis with LTV should be considered as a method for identification of patients at risk for clinically significant HCMV infection.


Subject(s)
Cytomegalovirus Infections , Hematopoietic Stem Cell Transplantation , Adult , Humans , Cytomegalovirus/genetics , T-Lymphocytes , Antiviral Agents/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Transplant Recipients , Peptides
2.
Transplant Cell Ther ; 28(4): 211.e1-211.e9, 2022 04.
Article in English | MEDLINE | ID: mdl-35042012

ABSTRACT

Letermovir (LTV), recently approved for the prophylaxis of human cytomegalovirus (HCMV) reactivation after hematopoietic stem cell transplantation (HSCT), has been shown to decrease the rate of infection in the first months post-transplantation. The aim of this study was to evaluate the impact of LTV prophylaxis on immune reconstitution and late-onset infection. We studied HCMV infection and HCMV-specific T cell reconstitution in 2 matched groups of HSCT recipients, those treated with LTV prophylaxis (n = 30; LTV group) and those receiving preemptive therapy (n = 31; PET group). We analyzed the rates of graft-versus-host disease (GVHD), neutropenia, baseline disease recurrence, and overall survival in the 2 groups. Clinically significant infections necessitating preemptive therapy showed a similar rate in the 2 groups (PET: 21 of 31 [68%]; LTV: 17 of 30 [57%]; P = .434) but occurred significantly later (after prophylaxis discontinuation) in the LTV group. There was no between-group difference in peak HCMV DNAemia level (P = .232). HCMV-specific T cell recovery was delayed by approximately 100 days in the LTV group. HCMV-specific CD4 and CD8 T cell counts were significantly lower in the LTV group at days 120 to 360 and days 90 to 120, respectively. A lower rate of chronic GVHD (P = .024) was seen in the LTV group. Time to engraftment, rate of disease relapse, and 1-year survival were not different between the 2 groups, whereas trends toward a lower rate of neutropenia (P = .124) and a higher rate of acute GVHD grade III-IV (P = .103) were observed in the LTV group. Because LTV prophylaxis delays HCMV infection and HCMV-specific immune reconstitution, immunologic and virologic monitoring should be implemented after discontinuation of prophylaxis. The potential effect of LTV prophylaxis in reducing chronic GVHD should be evaluated in prospective studies.


Subject(s)
Cytomegalovirus Infections , Hematopoietic Stem Cell Transplantation , Acetates , Cytomegalovirus , Cytomegalovirus Infections/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Neoplasm Recurrence, Local , Prospective Studies , Quinazolines
3.
Article in English | MEDLINE | ID: mdl-33587722

ABSTRACT

OBJECTIVE: The aim of this study was to analyze the clinical, radiologic, and biological features associated with human herpesvirus 6 (HHV-6) encephalitis in immunocompetent and immunocompromised hosts to establish which clinical settings should prompt HHV-6 testing. METHODS: We performed a retrospective research in the virology database of Fondazione IRCCS Policlinico San Matteo (Pavia, Italy) for all patients who tested positive for HHV-6 DNA in the CSF and/or in blood from January 2008 to September 2018 and separately assessed the number of patients meeting the criteria for HHV-6 encephalitis in the group of immunocompetent and immunocompromised hosts. RESULTS: Of the 926 patients tested for HHV-6 during the period of interest, 45 met the study criteria. Among immunocompetent hosts (n = 17), HHV-6 encephalitis was diagnosed to 4 infants or children presenting with seizures or mild encephalopathy during primary HHV-6 infection (CSF/blood replication ratio <<1 in all cases). Among immunocompromised hosts (n = 28), HHV-6 encephalitis was diagnosed to 7 adolescents/adults with hematologic conditions presenting with altered mental status (7/7), seizures (3/7), vigilance impairment (3/7), behavioral changes (2/7), hyponatremia (2/7), and anterograde amnesia (1/7). Initial brain MRI was altered only in 2 patients, but 6 of the 7 had a CSF/blood replication ratio >1. CONCLUSIONS: The detection of a CSF/blood replication ratio >1 represented a specific feature of immunocompromised patients with HHV-6 encephalitis and could be of special help to establish a diagnosis of HHV-6 encephalitis in hematopoietic stem cell transplant recipients lacking radiologic evidence of limbic involvement.


Subject(s)
Encephalitis, Viral/cerebrospinal fluid , Encephalitis, Viral/virology , Hematopoietic Stem Cell Transplantation , Herpesvirus 6, Human/pathogenicity , Roseolovirus Infections/cerebrospinal fluid , Roseolovirus Infections/virology , Adolescent , Adult , Antiviral Agents/cerebrospinal fluid , Antiviral Agents/pharmacology , Encephalitis, Viral/immunology , Female , Hematopoietic Stem Cell Transplantation/methods , Herpesvirus 6, Human/genetics , Herpesvirus 6, Human/immunology , Humans , Immunocompromised Host/immunology , Male , Retrospective Studies , Roseolovirus Infections/immunology , Seizures/immunology , Seizures/therapy , Seizures/virology , Young Adult
4.
J Clin Virol ; 135: 104734, 2021 02.
Article in English | MEDLINE | ID: mdl-33476929

ABSTRACT

Human cytomegalovirus (HCMV) infection is one of the major causes of mortality and morbidity after allo-hematopoietic stem cell transplantation (HSCT). Antiviral therapies are associated with toxicity and high economic burden. The aim of this retrospective study was to identify allo-HSCT HCMV-seropositive recipients at low risk of clinically significant HCMV infection who could avoid antiviral therapies. Sixty adult patients who underwent allo-HSCT were clustered in two groups: i) 22 (37%) spontaneously controlling HCMV reactivation (Controllers); ii) 38 (63%) developing clinically significant HCMV infection and receiving pre-emptive therapy (Non-Controllers). We analyzed several patient baseline characteristics, total/HCMV-specific CD4+ and CD8+ T-cell counts and their cytokine production (IFNγ, TNFα, IL2). Controllers presented a higher number of total/HCMV-specific CD4+ and CD8+ T-cells (P=0.001 and P=0.017 for total CD4+ and CD8+ T-cells respectively; P<0.001 for HCMV-specific T-cells) and a lower percentage of mono-functional IFNγ-producing HCMV-specific CD8+ T-cells (P=0.002). In bi-variable models, the prognostic impact of the percentage of mono-functional HCMV-specific CD8+ T-cells on treatment-free survival, adjusted for total/HCMVspecific CD4+ and CD8+ T-cells, was confirmed. An HCMV-seronegative donor was the only baseline characteristic associated with a clinically significant infection. These data, when confirmed by a larger prospective study, may provide information for guiding the personalized management of HCMV infection in allo-HSCT recipients.


Subject(s)
Cytomegalovirus Infections , Hematopoietic Stem Cell Transplantation , CD8-Positive T-Lymphocytes , Cytokines , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Prospective Studies , Retrospective Studies
5.
Int J Neurosci ; 130(8): 777-780, 2020 Aug.
Article in English | MEDLINE | ID: mdl-31906752

ABSTRACT

Objectives: Cranial neuropathies (CNs) can be due to a wide spectrum of causes, and the differential diagnosis is particularly challenging in patients with positive history of hematological malignancies, when neoplastic meningitis (NM) must be excluded.Patients and Methods: We retrospectively selected a series of twelve haematological patients with isolated cranial neuropathies (ICNs) or multiple cranial neuropathies (MCNs). among 71 patients that developed neurologic symptoms during different stages of the cancer, between 1 January, 2010 and 31 December, 2017. Brain and cauda equina magnetic resonance imaging (MRI) with gadolinium, cerebrospinal fluid (CSF) analysis, including flow cytometry for cell immunophenotyping and microbiological exams were performed in all patients.Results: Patients developed signs and symptoms of involvement of isolated (n = 11) or multiple (n = 1) cranial nerves, at different stages of the primary disease, and, in 5 of these cases in complete remission after hematopoietic stem cell transplantation. Among the 5 cases that eventually were diagnosed as having NM, cerebrospinal fluid was positive for neoplastic cells in 3, and MRI gadolinium-enhancement was present in 3. The other episodes were attributed to heterogeneous pathologies that were unrelated to meningeal infiltration by neoplastic cells.Conclusions: Our observations confirm that NM in haematological malignancies can yield insidious isolated signs of cranial nerves. Only a multidisciplinary approach allows prompt recognition of these conditions through a challenging process of differential diagnosis, and proper therapies.


Subject(s)
Cranial Nerve Diseases/diagnosis , Cranial Nerve Diseases/etiology , Leukemia/complications , Leukemia/diagnosis , Lymphoma/complications , Lymphoma/diagnosis , Meningeal Carcinomatosis/diagnosis , Adult , Brain/diagnostic imaging , Cauda Equina/diagnostic imaging , Cranial Nerve Diseases/cerebrospinal fluid , Cranial Nerve Diseases/pathology , Diagnosis, Differential , Female , Hematopoietic Stem Cell Transplantation , Humans , Leukemia/cerebrospinal fluid , Leukemia/pathology , Lymphoma/cerebrospinal fluid , Lymphoma/pathology , Magnetic Resonance Imaging , Male , Meningeal Carcinomatosis/cerebrospinal fluid , Meningeal Carcinomatosis/etiology , Meningeal Carcinomatosis/pathology , Middle Aged , Remission Induction , Retrospective Studies
6.
J Neurovirol ; 26(2): 257-263, 2020 04.
Article in English | MEDLINE | ID: mdl-31863400

ABSTRACT

The aim of this study was to review the quality of the diagnostic work-up for acute encephalitis carried out at our center in a cohort of patients with hematological disorders. Our data showed substantial heterogeneity in investigating patients. Not all patients had their CSF tested for viruses commonly responsible for encephalitis in immunocompetent individuals (e.g., VZV, enterovirus). A blood sample for the calculation of the CSF/blood replication ratio was collected in 74% of cases. CSF cultures and immunophenotyping of CSF cells were performed in 77% and 21% of patients, respectively. A multidisciplinary consensus is needed to improve current guidelines and standardize diagnostic protocols.


Subject(s)
Encephalitis/diagnosis , Encephalitis/etiology , Hematologic Diseases/complications , Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
7.
Biol Blood Marrow Transplant ; 25(12): 2388-2397, 2019 12.
Article in English | MEDLINE | ID: mdl-31400502

ABSTRACT

We performed a nationwide registry-based analysis to describe the clinical outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a tyrosine kinase inhibitor (TKI)-based treatment A total of 441 patients were included in the study. The median age at HSCT was 44 years (range, 18 to 70 years). All 441 patients (100%) received TKI before HSCT (performed between 2005 and 2016). Of these 441 patients, 404 (92%) were in cytologic complete remission (CR), whereas the remaining 37 (8%) had active disease at the time of HSCT. Molecular minimal residual disease (MRD) was negative in 147 patients (36%) at the time of HSCT. The donor was unrelated in 46% of patients. The most prevalent source of stem cells was peripheral blood (70%). The conditioning regimen was myeloablative in 82% of cases (total body irradiation-based in 50%) and included antithymocyte globulin in 51% of patients. With a median follow-up after HSCT of 39.4 months (range, 1 to 145 months), the probability of overall survival (OS) at 1, 2, and 5 years was 69.6%, 61.1% and 50.3%, respectively, with a median OS of 62 months. Progression-free survival (PFS) at 1, 2, and 5 years was 60.2%, 52.1% and 43.7%, respectively. OS and PFS were significantly better in patients who were in CR and MRD-negative at the time of HSCT compared with patients who were in CR but MRD-positive (50% OS not reached versus 36 months; P = .015; 50% PFS not reached versus 26 months, P = .003). The subgroup of MRD-negative patients both at HSCT and at 3 months after HSCT had a better outcome (5-year OS, 70%). Conversely, the 37 patients who underwent a HSCT with active Ph+ ALL had a median OS of 7 months and a median PFS of 5 months. The 5-year cumulative incidence of relapse was significantly lower in MRD-negative patients (19.5% versus 35.4%; P = .001). Nonrelapse mortality (NRM) after 1, 2, and 5 years was 19.1% (95% confidence interval [CI], 15.5% to 22.9%), 20.7% (95% CI, 17% to 24.7%), and 24.1% (95% CI, 20% to 28.5%), respectively. NRM was significantly lower with a modified European Society for Blood and Marrow Transplantation (mEBMT) risk score of 0 to 2 compared with ≥3 (15% versus 25%; P = .016). The median OS for Ph+ ALL patients who underwent a TKI-based treatment followed by an allogeneic HSCT, in recent years at the GITMO centers, was 62 months. Evaluation of the mEBMT risk score can be useful to predict NRM. Our data confirm that HSCT is a potentially curative treatment for Ph+ ALL with an excellent outcome for the subgroup of MRD-negative patients both at HSCT and at 3 months after HSCT (5-year OS, 70%).


Subject(s)
Hematopoietic Stem Cell Transplantation , Philadelphia Chromosome , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Registries , Adolescent , Adult , Aged , Allografts , Disease-Free Survival , Female , Humans , Italy/epidemiology , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Societies, Medical , Survival Rate
8.
Biol Blood Marrow Transplant ; 24(8): 1699-1706, 2018 08.
Article in English | MEDLINE | ID: mdl-29545186

ABSTRACT

Currently, no consensus has been reached on the optimal blood compartment to be used for surveillance of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) DNAemia. Although several comparative studies have been performed correlating CMV and EBV DNA loads in whole blood (WB) versus plasma, to our knowledge, no studies to date have analyzed the kinetics of both viruses in the 2 blood compartments. In this retrospective noninterventional multicenter cohort study, the kinetics of CMV and EBV DNA in 121 hematopoietic stem cell transplantation (HSCT) recipients were investigated by analyzing in parallel 569 and 351 paired samples from 80 and 58 sequential episodes of CMV and EBV DNAemia, respectively. Unlike previous studies, this study used a single automated molecular method that was CE-marked and Food and Drug Administration-approved for use in quantifying CMV and EBV DNA in both plasma and WB. Furthermore, the complete viral replication kinetics of all episodes (including both the ascending and the descending phases of the active infection) was examined in each patient. The previously observed overall correlation between CMV DNA levels in WB and plasma was confirmed (Spearman's ρ = .85; P < .001). However, although WB and plasma CMV DNAemia reached peak levels simultaneously, in the ascending phase, the median CMV DNA levels in plasma were approximately 1 log10 lower than WB. Furthermore, in patients who received preemptive therapy, CMV DNA showed a delayed decrease in plasma compared with WB. A lower correlation between EBV DNA levels in plasma versus WB was found (Spearman's ρ = .61; P < .001). EBV DNA kinetics was not consistent in the 2 blood compartments, mostly due to the lower positivity in plasma. Indeed, in 19% of episodes, EBV DNA was negative at the time of the EBV DNA peak in WB. Our results suggest a preferential use of WB for surveillance of CMV and EBV infection in HSCT recipients.


Subject(s)
Blood/virology , Cytomegalovirus/genetics , DNA, Viral/blood , Herpesvirus 4, Human/genetics , Plasma/virology , Transplant Recipients , Adult , Aged , Allografts , Female , Hematopoietic Stem Cell Transplantation , Humans , Kinetics , Male , Middle Aged , Retrospective Studies , Virus Replication
9.
Transplantation ; 101(3): 616-623, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27222935

ABSTRACT

BACKGROUND: Neurological complications (NC) after hematopoietic stem cell transplantation (HSCT) are rare events. The evolution of transplant procedures has resulted in improved survival and has allowed elderly patients or those with comorbidity to receive an HSCT. The risk of NC in these patients has still not been well defined. Therefore, we carried out an observational study to estimate the occurrence and identify the risks associated with NC. METHODS: The study cohort included 452 adult-allogeneic HSCT recipients, transplanted from 1997 to 2012. The median follow up was 1.3 year (0-15.7). A myeloablative regimen was used in 307 patients. Two hundred patients were grafted from matched unrelated donor (MUD), of these, 129 (64.5%) received an in vivo T-cell depletion. RESULTS: Out of 452 patients, 30 (6.6%) developed NC. Infections were the most frequent causes of NC (30%). Overall survival decreased in patients developing NC (P < 0.001). Univariate survival regression on the cumulative incidence of NC identified period of transplant, linear trend between 4-year periods (1997-2012) (P < 0.001), MUD (P < 0.001), and recipient's age (P = 0.034) as significant risk factors. In multivariate analysis, period of transplant (P < 0.001) and MUD (P = 0.004) remained significant independent risk factors. Matched unrelated donor recipients showed a 3.8-fold elevated risk of developing NC. CONCLUSIONS: Analysis highlights a temporal trend of incidence of NC that progressively increased over time and confirms a strong association between donor type and risk of NC. Our observations suggest that, although relatively uncommon, NC after allo-HSCT, may become more frequent due to the improved overall survival in recent years.


Subject(s)
Central Nervous System Diseases/epidemiology , Hematopoietic Stem Cell Transplantation/adverse effects , Adolescent , Adult , Age Factors , Aged , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/mortality , Central Nervous System Infections/epidemiology , Female , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cell Transplantation/mortality , Humans , Incidence , Italy/epidemiology , Linear Models , Male , Middle Aged , Multivariate Analysis , Myeloablative Agonists/therapeutic use , Proportional Hazards Models , Retrospective Studies , Risk Factors , Time Factors , Transplantation Conditioning , Transplantation, Homologous , Treatment Outcome , Unrelated Donors , Young Adult
10.
Neurology ; 81(11): 1014-7, 2013 Sep 10.
Article in English | MEDLINE | ID: mdl-23935180

ABSTRACT

Unusual late-onset complications of brain irradiation, characterized by reversible neurologic focal signs, seizures, and MRI alterations, have recently been reported and classified as stroke-like migraine attacks after radiation therapy (SMART)(1) and peri-ictal pseudoprogression (PIPG).(2.)


Subject(s)
Brain Diseases/etiology , Radiation Injuries/etiology , Radiotherapy/adverse effects , Adolescent , Adult , Brain Diseases/complications , Brain Diseases/diagnosis , Electroencephalography , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Radiation Injuries/complications , Radiation Injuries/diagnosis , Young Adult
11.
BMC Infect Dis ; 12: 238, 2012 Oct 03.
Article in English | MEDLINE | ID: mdl-23031364

ABSTRACT

BACKGROUND: Human cytomegalovirus (HCMV) infection of the central nervous system (CNS) is a rare but life threatening condition which may follow hematopoietic stem cell transplantation. Diagnosis, monitoring and treatment approaches rely on anecdotal reports. CASE PRESENTATIONS: The different outcomes of HCMV CNS disease in an adult and a pediatric T-cell depleted hematopoietic stem cell transplant (HSCT) recipient are reported. In the first case, HCMV encephalitis emerged in the context of simultaneous impairment of the T- and B-cell immunity. Antiviral treatment only reduced viral load in peripheral blood and the patient died. In the second case, an HCMV radiculopathy was observed and antiviral treatment was adjusted on the basis of intrathecal drug level. In addition, donor HCMV-specific cytotoxic T lymphocytes (CTLs) were infused. Viral load in the CNS decreased and the patient recovered from the acute event. In neither case were drug-resistant HCMV variants observed in blood or CNS samples. CONCLUSIONS: T-cell depleted HSCT appears a predisposing condition for CNS HCMV infection since never observed in other HSCT recipients at our center in the last 15 years. Intensive diagnostic approaches and timely aggressive combination treatments might improve clinical outcome in these patients.


Subject(s)
Antiviral Agents/administration & dosage , Cytomegalovirus Infections/pathology , Encephalitis, Viral/pathology , Hematopoietic Stem Cell Transplantation , Radiculopathy/pathology , Adoptive Transfer , Blood/virology , Cerebrospinal Fluid/virology , Child, Preschool , Cytomegalovirus Infections/drug therapy , Encephalitis, Viral/drug therapy , Fatal Outcome , Female , Humans , Male , Middle Aged , Radiculopathy/drug therapy , T-Lymphocytes, Cytotoxic/immunology , Treatment Outcome , Viral Load
12.
New Microbiol ; 30(3): 255-8, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17802904

ABSTRACT

From October 2004 through October 2006 a study was performed to evaluate the prevalence of human Metapneumovirus (hMPV) infection in adult hematopoietic stem cell transplant (HSCT) recipients. Sequential nasopharyngeal aspirates (NPA) were collected independently from respiratory symptoms and evaluated for hMPV-RNA by polymerase chain reaction (PCR) and sequence analysis. Results indicate epidemiological and molecular differences between the 2004-2005 and 2005-2006 periods and that hMPV seems not to symptomatically affect HSCT patients or cause late respiratory sequelae. In addition, data collected suggest a hospital origin of hMPV infection in most HSCT patients during the 2004-2005 period.


Subject(s)
Hematopoietic Stem Cell Transplantation , Metapneumovirus/genetics , Paramyxoviridae Infections/epidemiology , Respiratory Tract Diseases/epidemiology , Acute Disease , Adult , Carrier State , Cross Infection/epidemiology , Cross Infection/etiology , Humans , Infant , Infant, Newborn , Italy/epidemiology , Longitudinal Studies , Metapneumovirus/isolation & purification , Nasopharynx/virology , Paramyxoviridae Infections/etiology , Polymerase Chain Reaction , Prevalence , RNA, Viral/genetics , Respiratory Tract Diseases/virology , Reverse Transcriptase Polymerase Chain Reaction , Seasons , Sequence Analysis
13.
J Infect Dis ; 194(4): 474-8, 2006 Aug 15.
Article in English | MEDLINE | ID: mdl-16845630

ABSTRACT

Sequential nasopharyngeal aspirates from patients without respiratory symptoms undergoing hematopoietic stem cell transplantation (HSCT) were tested for genomic RNA of human metapneumovirus (hMPV). Persistent hMPV infection was documented in most of them and confirmed by virus isolation. hMPV infection etiology was also evaluated during the same period in samples from pediatric patients with acute respiratory diseases (ARDs). Sequence analysis of hMPV in HSCT recipients documented infection by hMPV genotype A and strong interhost similarity; this pattern differs from that observed in pediatric patients with ARDs. The data indicate that HSCT recipients may frequently develop symptomless hMPV infection.


Subject(s)
Hematologic Neoplasms , Hematopoietic Stem Cell Transplantation , Metapneumovirus/isolation & purification , Paramyxoviridae Infections/epidemiology , Pneumonia, Viral/epidemiology , Adult , Child, Preschool , Female , Humans , Immunocompromised Host , Incidence , Infant , Infant, Newborn , Italy/epidemiology , Male , Metapneumovirus/genetics , Middle Aged , Nasopharynx/virology , Paramyxoviridae Infections/virology , Pneumonia, Viral/virology , Prospective Studies , RNA, Viral/analysis , Reverse Transcriptase Polymerase Chain Reaction , Seasons
SELECTION OF CITATIONS
SEARCH DETAIL
...